Palvella's QTORIN™ Rapamycin Phase 3 SELVA Study Meets Primary & Secondary Endpoints in Rare Skin Disease
PVLA has more than doubled off its 52-week low of $18.225 on light trading volume (0.2× avg).
Summary
Palvella Therapeutics announced that its QTORIN™ rapamycin Phase 3 SELVA study for microcystic lymphatic malformations successfully met its primary endpoint with statistically significant improvement, as well as all key secondary endpoints. This positive clinical trial data, highlighted in poster presentations at the American Academy of Dermatology Annual Meeting, is a significant development for the company's lead product candidate targeting a serious, rare skin disease with no FDA-approved therapies. The successful Phase 3 readout is a material de-risking event for Palvella, demonstrating the efficacy of QTORIN™ rapamycin. Investors will now focus on the company's next steps regarding regulatory submissions and potential commercialization plans.
At the time of this announcement, PVLA was trading at $115.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $18.23 to $151.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.